New CREGS Insights: Cerebrolysin^® Benefits Stroke Patients with Diabetes

Diabetes is highly prevalent among patients with ischemic stroke and is associated with poorer clinical outcomes and a higher long-term vascular risk. Therefore, recovery for patients with diabetes, can be particularly challenging.

At the World Stroke Congress 2026, an interesting new subgroup analysis from CREGS explored an important question: Can patients with diabetes especially benefit from Cerebrolysin^® following moderate acute ischemic stroke? The analysis looked at 90-day outcomes in patients with diabetes from the prospective CREGS study.

Promising new insights for a hard-to-treat patient group

By Day 90, add-on treatment with Cerebrolysin^® led to significantly better functional (mRS: MW 0.6435; P < 0.0001) and neurological outcomes (NIHSS: MW 0.5738; P = 0.0033) compared with standard therapy alone.

Reference: Abstracts from the 18th World Stroke Congress, 21-23 October 2026, Seoul, Korea. International Journal of Stroke. 2026;21(2_suppl):3-412.
doi:10.1177/17474930261484004, page 21, ID1162

Importantly, these findings were directionally consistent with the results observed in the overall CREGS target population.

Why does this matter?

Patients with diabetes represent an important high-risk population. These new findings add to the growing evidence related to Cerebrolysin^® and suggest that its benefits on recovery may also extend to stroke patients with diabetes.

Please also see the poster below which was presented at the WSC 2026 and explore the results of this CREGS subgroup analysis.